Prospective observational study of biomarkers to predict efficacy after Pembrolizumab in patients with PD-L1 positive advanced non-small cell lung cancer.
Not Applicable
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000026793
- Lead Sponsor
- Gunma University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
Judgement as exclusion by chief mdical physians having auto-immune diseases
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What biomarkers correlate with Pembrolizumab efficacy in PD-L1 positive NSCLC patients in JPRN-UMIN000026793?
How does PD-L1 expression influence Pembrolizumab outcomes in advanced NSCLC observational studies?
What molecular mechanisms underlie Pembrolizumab resistance in PD-L1 positive NSCLC populations?
Are there predictive biomarkers for Pembrolizumab response beyond PD-L1 in non-small cell lung cancer?
What adverse events are associated with Pembrolizumab in PD-L1 positive NSCLC observational trials?